Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
True but we need to see those number to know what we truly have here.
When is the question not if
Would love to see it break out here there shouldn't be much coming for sale at this point? Thoughts?
They say good things come to people that wait for it.
I have officially waited long enough.
Now bring it!
Fidelity just gave it to me....thanks
Ok thank you for the try.
I agree do you have a link so I can view the level 2?
I may want to buy some more imaginary shares.
Does anyone have a working level 2 link that they can post, mine is down this morning?
Spot on!!!
Thank you so much! Very positive news for our stock.
Can someone please post the actual pr?
Me as well!
Oh and buying some more.
So quite on the board today?
Stocks looking good, just a matter of the results being announced.
Almost all here are betting they will be off the charts and I still believe this to be true based on my own dd.
News won't come this week being its a holiday in my opionion.
Anticipating next week the wait will be over. But it's just the begging of huge things to come.
Not at all. Patience
I just bought some more imaginary shares just now, not even a double print.
Very apparent the shares were shorted to me.
Bullshit
Bullshit
Thanks my man!!
Nothing to worry about, but thanks for watching so closely.
Probably a good time to buy IMHO over the long haul.
They probably think it's cheap here
I do!
News out yet again
LIVINGSTON, NJ--(Marketwired - September 22, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its recently formed Joint Venture, Milestone Ophthalmic Sp. z o.o., plans to merge with Emmerson Wierzytelnosci Hipoteczne S.A. ("EWH") to effect a listing of its common stock on the New Connect market of the Warsaw Stock Exchange, subject to certain final terms and conditions of the merger agreement.
Milestone Ophthalmic's planned merger with EWH follows a recent agreement between Astoria Capital S.A. and Milestone Scientific, Inc., whereby the two companies formed Milestone Ophthalmic Sp. z o.o. Under the agreement, Milestone Scientific, Inc. will grant Milestone Ophthalmic the worldwide exclusive rights to its technology for use in intravitreal injections ("Ophthalmic Instrument"). Intravitreal injection is the placement or delivery of medications or other substances into the eye.
Milestone Scientific will receive 25% of the total equity in Milestone Ophthalmic for assistance in management of Milestone Ophthalmic and commercialization of the Ophthalmic Instruments. Milestone Ophthalmic will pay Milestone Scientific a 7% royalty on any instruments sold and $1 million of license fees as certain targets are achieved. Milestone Ophthalmic will also provide financing of up to USD $2.5 million for development and commercialization of the Ophthalmic Instrument, including regulatory costs.
In connection with the merger, EWH will hold a general meeting of shareholders on September 26, 2014 in which the majority shareholders are expected to approve the name change from "EWH S.A" to "Advanced Ocular Sciences S.A." and vote for new Management and Supervisory Board members, including individuals affiliated with Milestone Scientific, Inc. and Astoria Capital S.A.
Milestone's patented technology regulates and controls the flow rate of fluid, minimizing tissue damage and allowing for painless injection. The Dynamic Pressure Sensing® (DPS) capability provides visual and audible in-tissue pressure feedback. DPS provides medical practitioners the ability to identify tissue types and inject drugs at precisely the right location, eliminating guesswork. Additionally, the disposable injection handpiece allows for precise tactile control during an injection.
Intravitreal injections have become a cornerstone of retinal care and one of the most commonly performed procedures across all specialties. According to the American Medical Association, Intravitreous (IVT) injections are the fastest growing procedure in ophthalmology. The number of IVT injections has increased from more than 3,000 per year in 1999 to more than 1 million injections in 2008 to more than 2 million injections in 2012 and the number of injections will continue to increase as the population ages.
There are a variety of complications that could potentially be reduced or avoided using this technology, including: bleeding (subconjunctival, vitreous hemorrhage); retinal tear / detachment; cataract (from inadvertently hitting the lens); increased intraocular pressure (IOP) with potential to damage the optic nerve; as well as other risk factors.
The ophthalmic market represents a sizable opportunity. Ophthalmologists still use hypodermics to deliver drugs to the eye, a technology that has barely evolved since the 1800s. Milestone's technology has been utilized in other applications such as dentistry, where it has an established track record and safety profile.
Tadeusz Poplawski, CEO of EWH, commented, "We look forward to completing the merger with Milestone Ophthalmic. We see enormous worldwide market potential for the Ophthalmic Instrument, especially given the aging population and the rate at which IVT injections are being utilized. We believe this technology has the potential to help improve the treatment of eye diseases such as age-related macular degeneration, diabetic retinopathy, macular edema, and retinal vein occlusion, while improving safety of the injection for the patient and reducing malpractice risk for the medical practitioner."
Leonard Osser, CEO of Milestone Scientific, stated, "We look forward to listing Milestone Ophthalmic's shares on the New Connect market and we are currently working with WDM to raise capital for Milestone Ophthalmic in Poland as well as apply for grant funding, which will help accelerate our plans for introducing this technology to the European market and worldwide. We believe the structure of this agreement, which includes non-dilutive funding provided by Milestone Ophthalmic, along with license fees and royalties to Milestone Scientific, demonstrates once again our ability to bring medical instruments to market while minimizing dilution for shareholders."
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
About WDM
WDM is Central and Eastern Europe's leading small cap investment bank. It has been listed on the Warsaw Stock Exchange since 2007. Over the past 6 years, WDM has taken over 50 companies public on the Warsaw Stock Exchange. It has raised over $150,000,000 in private equity, venture capital and public financing for its clients. WDM's investment management subsidiary, WDM Capital, manages a growing portfolio of some of the region's most promising micro caps. WDM's United States subsidiary, WDM Capital USA, provides access to CEE financing and investment opportunities for North American clients and North American financing and market access for CEE clients. For more information visit: www.wdmcapital.com
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
Thank you for the clarification and I agree that can very like be the used.
Great info, thanks for digging this up, that being said this doesn't look like a mobile instrument therefore I'm thinking this is not the sport.
Bottom line a company update is needed and overdue at this point. IMHO.
Can you say transparency.
Part of this game is knowing how to play it and make investors interested.
Every move has to be more calculated in this situation.
All they do is keep on putting out time restrictions, not smart but the land can out smart everyone if better than 20 plus billion IMHO.
On a side note I cant buy any on the bid, .291 for 5000 yes it me and I have so much it doesn't matter if I don't get filled so jump me as this is going higher.
We shouldn't have to know what if.
If that's the case put it out there.
Good for investors and transparency.
Ok I'm done now.
With all due repect if that's their plan and news isn't coming today than the company should announce it.
Since they said they were coming by tomorrow I feel they have to update their shareholders.
Good results or not.
Chin up tea bags in my throat knees bent.
Welcome to the board are you long the stock?
Big news huge market
Milestone Scientific Receives CE Mark Approval for Epidural Injection System
LIVINGSTON, NJ--(Marketwired - September 18, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its subsidiary, Milestone Medical, has received CE Mark to market and sell its epidural injection system in Europe. The CompuFlo™ Epidural Computer Controlled Anesthesia System (CompuFlo™ Epidural Model 6000) is intended for the verification of needle tip placement in the lumbar epidural space in patients over age of 18 and the delivery of medication and other fluids in a controlled manner in the lumbar epidural space as part of an in-patient or out-patient procedure established by their Health Care Provider.
Leonard Osser, Chief Executive Officer of Milestone Scientific, stated, "CE approval for our subsidiary's epidural instrument follows the recent CE approval of its intra-articular instrument. CE approval is an important achievement and further validation of our technology as our subsidiary moves towards commercial sale of the epidural injection system. Our subsidiary's next steps involve securing strategic partners to distribute its products in Europe, as it has already done in the U.S. Injection technology has not changed meaningfully since the advent of the hypodermic syringe over 150 years ago. Millions of patients that require epidural drug delivery and millions of women who give birth each year choose not to have an epidural due primarily to safety concerns about the high risks associated with this injection. Epidurals represent a multi-billion dollar global market and we believe our technology can transform these injections from an art to a science."
Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other application of controlling the pain that patients typically associate with injections.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
My sources tell me tomorrow pre open is the time!
GLTA.
Lift off.....please stand back.
100,000 traded off the open.
Looks like we should see 52 week highs shortly based on the recent PR's
Thanks Jet Man respect your posts always!!
I'm not selling, not me.
I may buy some more pre news.
The is a once in a lifetime opportunity!
Were literally invested and sitting on a Gold Mine!!!!!
I do agree with you there, that's why we now need news to come sooner than later.
Why would you keep on saying it's coming now oh it coming next week.
Just get it in hand and feed it to the market.
It's that simple.
I feel it in my tea bag an my tea bag always knows!!
It is sooo quite on the board today, it can only mean one thing.
It's the quite before the storm.
Tomorrow is the time.
Bmakn clearing off the inside offer here we go!!
See below quote from the most recent 8-K from 9-11-14:
"I would like to thank all shareholders for your patience and support, as we know this technology process has taken much longer than expected. Many of the delays attributable to the geophysical ground results were due to the unrest that exists today in the Ukraine, and thankfully have been completed.
I hope this information will allow you to better appreciate the ground results that we will be reporting next week."
Not sure why anyone on the message board is stating news to come in 10 days.
News is coming this week as per the chairman! It doesn't get any clearer than this IMHO.
News out
Milestone Scientific and Milestone China Form New Dermatological Joint Venture
LIVINGSTON, NJ--(Marketwired - September 16, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced it has formed a dermatological joint venture with Milestone China. The new joint venture entity, Milestone Advanced Cosmetic Systems, Inc., will be 50% owned by Milestone Scientific and 50% owned by Milestone China. Milestone China will contribute $900,000 and Milestone Scientific will contribute a limited license to use its technology to the joint venture for the development of a botox injection system, consisting of a computer controlled injection device and a related disposable. As previously announced, Milestone China is a joint venture distribution company between Milestone Scientific and a team headed by a senior healthcare executive from China. The focus of Milestone China is to supply and distribute medical and dental instruments, and disposables to China and other Asian markets.
The joint venture will have exclusive world-wide rights to the botox drug delivery system, which will be based on the patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific. Milestone Scientific will be responsible for sales and distribution of the instrument in the USA and Europe, while Milestone China will oversee sales and distribution of the instrument in China and other parts of Asia. The joint venture plans to commence development of the device and disposable within the next ninety days.
Leonard Osser, Chief Executive Officer of Milestone Scientific, stated, "Our new joint venture represents the next step of expanding our intellectual property and proven technology into new markets. Botox injections represent a growing multi-billion dollar worldwide market. However, the procedure can be painful and can result in complications due to improper drug delivery. We believe our system will help address these challenges and should be well received by the market as a painless and effective means of drug delivery. Milestone China is an ideal strategic partner, as the principals have extensive expertise and proven track records launching new medical devices in China. This latest agreement reinforces our strategy of leveraging our core technology, and strategically entering new markets while minimizing dilution for shareholders."
Lidong Zhang, Chief Executive Officer of Milestone China, added, "With over 50 million injections delivered to date, Milestone Scientific's painless, computer controlled injection and drug delivery technology is ideally suited to address the botox market. We look forward to working with Milestone Scientific to develop the Botox delivery system and help launch the product in China and Asia. We believe this technology has the potential to become the standard of care, as medical practitioners realize the safety and medical benefits of this system."
About Milestone Scientific Inc.
Milestone Scientific Inc. is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.